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Abstract
Objective—We assessed the effect of prenatal and peripartum antibiotics on maternal morbidity
and mortality among HIV-infected and uninfected women.
Methods—A multicenter trial was conducted at clinical sites in 4 Sub-Saharan African cities:
Blantyre and Lilongwe, Malawi; Dar es Salaam, Tanzania; and Lusaka, Zambia. A total of 1558
HIV-infected and 271 uninfected pregnant women who were eligible to receive both the prenatal and
peripartum antibiotic/placebo regimens were enrolled. Pregnant women were interviewed at 20–24
weeks of gestation and a physical examination was performed. Women were randomized to receive
either antibiotics or placebo. At the 26–30 week visit, participants were given antibiotics or placebo
to be taken every 4 hours beginning at the onset of labor and continuing after delivery 3 times a day
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until a 1-week course was completed. Logistic regression and Cox proportional hazards models were
used.
Results—There were no significant differences between the antibiotic and placebo groups for
medical conditions, obstetric complications, physical examination findings, puerperal sepsis, and
death in either the HIV-infected or the uninfected cohort.
Conclusion—Administration of study antibiotics during pregnancy had no effect on maternal
morbidity and mortality among HIV-infected and uninfected pregnant women.
Keywords
Antibiotics; HIV; Maternal morbidity; Maternal mortality; Pregnancy
1. Introduction
Pathogenic bacteria that are common inhabitants of the vagina may cause infections such as
cervicitis, chorioamnionitis, and intra-amniotic infection during pregnancy. For example,
bacterial vaginosis is a common condition in which the normal vaginal lactobacilli are replaced
by a mixture of bacteria including Gardnerella vaginalis, Mobiluncus spp, Bacteroides spp,
and Mycoplasma hominis. These same organisms are frequently found in intrauterine
infections, especially of the chorioamnion. Such infections are known to have an important
role either as a cause or a consequence of preterm labor or premature rupture of membranes
(PROM) and subsequent preterm birth [1,2].
Antibiotic prophylaxis given during the second and third trimesters of pregnancy may prevent
or treat such infections and hence reduce the risk of preterm labor or PROM when given
routinely to pregnant women. In a randomized clinical trial of antibiotics in women at risk of
endometritis in United States, administration of cefotetan and doxycycline/erythromycin
resulted in a reduced frequency of postpartum endometritis [3]. Similarly, in a recent
randomized controlled trial of prophylactic antibiotics to prevent postpartum infectious
morbidity in HIV-infected women who delivered vaginally, a single intrapartum prophylactic
dose of cefoxitin was shown to significantly reduce (13.6% in placebo vs 6.4% in antibiotic
group) postpartum endometritis [4]. Other antibiotic studies showed no benefit in reducing
maternal morbidity [5–7]. A trial of antibiotics using metronidazole, erythromycin, and
ampicillin (HPTN 024 study) conducted among HIV-infected and uninfected pregnant women
to prevent chorioamnionitis-associated mother-to-child transmission (MTCT) of HIV and
preterm birth showed that these antibiotics did not reduce either the risk of MTCT of HIV or
the rate of preterm birth [8,9]. However, there is a relative paucity of research on whether these
antibiotic regimens affect maternal health outcomes, particularly in populations with HIV-1
infection. The aim of the present study was to investigate the effects of antibiotic administration
prenatally and during labor on maternal morbidity and mortality among HIV-infected and
uninfected pregnant women enrolled in the HPTN 024 study.
2. Materials and methods
HPTN 024 was a randomized, double-blinded, placebo-controlled Phase III trial that enrolled
both HIV-infected and HIV-uninfected women. The primary objectives of this trial were to
determine the efficacy of a low-cost antibiotic intervention for prevention of chorioamnionitis-
associated MTCT of HIV and of preterm birth [8]. This multicenter trial was conducted at
clinical sites in 4 Sub-Saharan African cities: Blantyre and Lilongwe, Malawi; Dar es Salaam,
Tanzania; and Lusaka, Zambia. Enrollment started in July 2001 and ended in February 2003.
The design and results of the HPTN 024 trial have been described in detail elsewhere [8,9].
Briefly, pregnant women (between 20 and 24 weeks of pregnancy) were randomized to receive
Aboud et al. Page 2
Int J Gynaecol Obstet. Author manuscript; available in PMC 2010 December 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
either antibiotics (250 mg of metronidazole 3 times a day and 250 mg of erythromycin orally
3 times a day for 7 days) or placebo. The antibiotics and dosages were chosen because they
were generally effective against the vaginal and intrauterine organisms and reduction in
preterm birth may be achieved using a prolonged course of antibiotics (1 week or more) in the
second trimester. Data regarding socio-demographic characteristics as well as obstetric and
medical history were obtained through participant interviews. The external genitalia, vagina,
and cervix were examined, and a bimanual examination was performed. In addition to physical
examination, laboratory tests were performed (including HIV testing, quantification of CD4
cell counts and plasma viral loads, and screening for syphilis, trichomoniasis, candidiasis,
bacterial vaginosis, gonorrhea and Chlamydia infection) [8]. In addition, at the 26–30 week
visit, participants were given antibiotics (250 mg of metronidazole and 500 mg of ampicillin)
or placebo to be taken at the onset of labor and then every 4 hours, continuing after delivery 3
times a day until the 1-week course was completed. Compliance with treatment was assessed
using pill counts at the 26–30 week visit as described previously [8]. Women were asked to
bring the peripartum antibiotics/placebo blister packs to the next study visit at 4–6 weeks post
partum. Adherence was assessed by the number of pills missing from the blister pack at the
follow-up visit. If the blister packs were not returned, reported use was noted. Adherence to
prenatal study drugs was assessed among 1562 (99%) of the 1573 women randomly assigned
and delivered before March 5, 2003. Of these, 98% in each study arm took all 21 tablets of
metronidazole and erythromycin prenatally. Adherence was also high at the time of labor: 1392
(88%) of the 1573 women took at least one dose before delivery. Physical examinations during
pregnancy, at delivery, discharge, and within 3 months after delivery were performed to
determine the mothers’ medical conditions and obstetric complications. The HPTN 024 trial
revealed that, despite reducing vaginal infections, the antibiotic regimen used did not reduce
preterm birth, increase the time to delivery, or increase birth weight [9]. HIV-infected women
and their infants were offered MTCT prophylaxis with nevirapine [10]. Mothers’ medical
conditions and obstetric complications (including postpartum hemorrhage) were managed
according to the existing obstetrics management guidelines in the individual countries
(including the use of active management of the third stage of labor and use of oxytocic agents).
Data presented at an interim Data Safety Monitoring Board (DSMB) showed that the antibiotic
regimen did not show a meaningful reduction of MTCT of HIV. Thus, further randomization
and distribution of study drugs was halted on March 5, 2003 at all study sites.
Because of the early termination of the trial by the DSMB, this analysis includes only those
HIV-infected and uninfected pregnant women who were eligible to receive both the prenatal
and peripartum antibiotic/placebo regimens. These were the women who were randomized on
or before October 15, 2002. This date was determined by subtracting 140 days from March 5,
2003, assuming a woman entered the study at a gestational age of 20 weeks and the normal
course of pregnancy is 40 weeks.
We examined the effect of antibiotics versus placebo on a number of maternal medical
conditions and physical examination findings including diarrhea (3 or more loose and watery
stools per day over the last 2 weeks); cough (coughing all day for more than 2 weeks); fever
(hot to touch for more than 2 weeks); recurrent itchy vaginal discharge; herpes zoster; oral
thrush; hospitalization; weight gain or loss during pregnancy; mastitis; puerperal sepsis; and
death. Information on diarrhea, cough, fever, itchy vaginal discharge, and hospitalization was
collected at enrollment, the first and second prenatal visits, the intrapartum visit, and follow-
up visits post delivery. Data regarding fever during labor or post partum; prenatal or postpartum
hemorrhage; and hypertension with or without proteinuria were collected at the intrapartum
visit. Information on puerperal sepsis and admission to the postnatal ward was collected at the
time of maternal discharge from the hospital. Weight was measured at enrollment, the first and
second prenatal visits, and at discharge. Mastitis was defined as inflammation of the breast
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occurring within 3 months post delivery. Data related to syphilis risk factors, prevalence, and
birth outcomes in the HPTN 024 cohort have been published [11].
This was a planned secondary analysis. The sample size in the original study design (i.e. 1560
women in each arm) would provide adequate power to detect a medium or large effect in the
target medical conditions between the treatment arms. With the sample size used in this analysis
(i.e. 779 HIV-infected women in each arm), the power is less adequate, especially when the
medical condition is rare or the expected effect size is small. To assess differences in baseline
characteristics (including demographics, laboratory results, obstetric and medical history, and
medical conditions/physical examination findings) between the antibiotic and the placebo
arms, Pearson χ2 or Fisher exact test P values were reported for categorical variables, and 2-
sample t test or Wilcoxon rank sum test P values were calculated for continuous variables. For
medical conditions for which data were collected on multiple occasions, generalized estimating
equations (GEE) models were used to compute the odds of having a condition in the antibiotics
arm versus the placebo arm, while adjusting for baseline conditions. A logistic regression
model was utilized to analyze binary outcomes that were collected only once during follow-
up. A Cox proportional hazards model was used to estimate treatment effect on death. Weight
gain was defined as the average per-week weight change from enrollment to the second prenatal
visit or the first one thereafter if a woman missed her second visit. A general linear model was
used to ascertain the effect of treatment on weight gain adjusting for gestational age at
enrollment (measured by fundal height in centimeters). Analyses on the effect of the
intervention were performed separately for HIV-infected and uninfected cohorts. P <0.05 was
regarded as statistically significant. All statistical analyses were performed using SAS version
9.1.3 on SunOS 5.9 platform (SAS, Cary NC, USA).
Written informed consent was obtained from all participants prior to HIV testing and inclusion
in the study. The study protocol was approved by U.S. institutional review boards (Bloomberg
School of Public Health, Johns Hopkins University, Baltimore, MD; School of Medicine,
University of Alabama at Birmingham; School of Medicine, University of North Carolina at
Chapel Hill; Harvard University School of Public Health, Boston, MA) and by institutional
ethical review boards/committees (University of Malawi College of Medicine, Lilongwe,
Malawi; Muhimbili University College of Health Sciences, Dar es Salaam, Tanzania; and the
University of Zambia School of Medicine, Lusaka, Zambia).
3. Results
Of the 2659 women enrolled in HPTN 024, 1829 women (1558 HIV-infected and 271 HIV-
uninfected) met the inclusion criteria for this analysis (Figure 1). Baseline characteristics of
women by randomization arms were comparable in both the HIV-infected cohort (Table 1)
and the HIV-uninfected cohort (Table 2).
There were no statistically significant differences observed in the occurrence of clinical
conditions such as mastitis, diarrhea in the previous 2 weeks, fever or cough for more than 2
weeks in the last 3 months, vaginal discharge or herpes zoster in the last 3 months, oral thrush
in the last month, or hospitalization between the placebo and the antibiotic arms in either the
HIV-infected or the HIV-uninfected cohorts within 3 months after delivery (Table 3).Eighteen
deaths occurred in the HIV-infected cohort, 10 in the antibiotics arm and 8 in the placebo arm.
A non-significant increase in the survival time was observed in the antibiotic group, either
stratifying (Hazard ratio 1.23; 95% CI, 0.49–3.12) or not stratifying by site (Hazard ratio 1.22;
95% CI, 0.49–3.08). No deaths occurred in the HIV-uninfected cohort. There was no significant
difference in average weight gain during pregnancy between the antibiotic and placebo arms
in either the HIV-infected (0.29 vs 0.26 kg; P=0.12) or the HIV-uninfected (0.29 vs 0.31 kg;
P=0.77) cohort.
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4. Discussion
Pregnancy is a physiological state in which immune function is expected to be compromised,
particularly in HIV-infected women. Therefore, preventing or treating subclinical infections
could have a beneficial effect on maternal and infant morbidity and mortality. However, the
results of the current analysis indicate there are no significant differences in morbidity or
mortality in either the HIV-infected or HIV-uninfected cohorts according to randomization
arm (antibiotics vs placebo). Similarly, there was no significant difference in average weight
gain during pregnancy between the antibiotic and placebo arms.
Several trials have been conducted previously with various chemoprophylactic regimens to
determine their effects on pregnancy outcomes and neonatal morbidity. A relatively successful
application of chemoprophylaxis has been seen in prolongation of the latency period between
the rupture of membranes and delivery, thus increasing the gestational age at birth [3,12,13].
Results of the HPTN 024 trial showed that there were few differences in mean gestational age
at delivery, the percentage of preterm births, the time between randomization and delivery, or
birth weight between antibiotic- versus placebo-treated HIV-infected and uninfected women
[9]. Four weeks after the 24-week antibiotic/placebo course, bacterial vaginosis and
trichomoniasis were reduced by 49% to 61% in the antibiotic compared with the placebo groups
[9]. Overall the antibiotics used did not show benefit in reducing MTCT or preterm birth.
Our study findings showed that there was no effect of antibiotics on mastitis and pyrexia in
HIV-infected women. Similar findings have been reported previously [4]. In the current study,
metronidazole and erythromycin were given at 20 to 24 weeks of gestation for 7 days while
metronidazole and ampicillin were taken during labor through 1 week post partum. In the
previous study a single dose of cefoxitin was given intrapartum at 36 weeks or more of gestation
[4]. Possible effects of other co-interventions including the use of active management of the
third stage of labor and oxytocic agents could possibly have impacts on the rates of postpartum
hemorrhage and also indirectly on puerperal sepsis. These interventions may reduce the
statistical power of our analyses, but since the patients were randomized this would not affect
the validity of results of the trial. In addition, we found no effect of antibiotics on other maternal
morbidity or mortality. Our study findings may suggest that since pregnancy is associated with
weight gain, and increases of intravascular volume, glomerular filtration, and hepatic
metabolism, 250 mg of erythromycin orally 3 times a day administered for 7 days may have
not been sufficient for infection prophylaxis during pregnancy. In addition, maternal plasma
levels of antibiotics reach values 10%–15% under the ranges observed with the same dosages
administered to non-pregnant women [14].
A limitation of our analyses on the efficacy of antibiotics on maternal health outcomes is the
relatively small number of events for the medical and obstetric endpoints. This is likely to
compromise the statistical power to detect real differences between the antibiotic and the
placebo groups. Future research with a larger sample sizes as well as different and potentially
more effective yet safe antibiotic regimens is, therefore, needed to further elucidate the effect
of antibiotic use on maternal health outcomes.
It is concluded that administration of study antibiotics during pregnancy had no effect on
amaternal morbidity and mortality among HIV-infected and uninfected pregnant women.
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Figure 1.
Derivation of the study population
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